You are here: Home » Current Affairs » Coronavirus » News
Business Standard

New blood test predicts which Covid-19 patients are at severe risk

In the fight against novel coronavirus, scientists have developed a score that can accurately predict which patients will develop a severe form of Covid-19

Topics
blood | Coronavirus

IANS  |  London 

doctors, patients, medical, health, hospitals, coronavirus, plasma, covid, blood

In the fight against novel coronavirus, scientists have developed a score that can accurately predict which patients will develop a severe form of Covid-19.

The measurement, called the Dublin-Boston score, is designed to enable clinicians to make more informed decisions when identifying patients who may benefit from therapies, such as steroids, and admission to intensive care units.

Until this study, no Covid-19-specific prognostic scores were available to guide clinical decision-making.

According to the findings, published in the journal EBioMedicine, the Dublin-Boston score can now accurately predict how severe the infection will be on Day 7 after measuring the patient's for the first four days.

"The Dublin-Boston score is easily calculated and can be applied to all hospitalised Covid-19 patients," said study author Gerry McElvaney from the RCSI University in Ireland.

The test works by measuring the levels of two molecules that send messages to the body's immune system and control inflammation.

One of these molecules, interleukin (IL)-6, is pro-inflammatory, and a different one, called IL-10, is anti-inflammatory. The levels of both are altered in severe Covid-19 patients.

Based on the changes in the ratio of these two molecules over time, the researchers developed a point system where each 1-point increase was associated with 5.6 times increased odds for a more severe outcome.

"More informed prognosis could help determine when to escalate or de-escalate care, a key component of the efficient allocation of resources during the current pandemic," McElvaney said.

"The score may also have a role in evaluating whether new therapies designed to decrease inflammation in Covid-19 actually provide benefit," McElvaney added.

--IANS

bu/bg

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, October 16 2020. 19:21 IST
RECOMMENDED FOR YOU